Soluble Epoxide Hydrolase Inhibition Protects the Kidney from Hypertension-Induced Damage

Journal of the American Society of Nephrology

Volumn 15, Issue 5, 2004, Pages 1244-1253

  Zhao, Xueying ^a   Yamamoto, Tatsuo ^c   Newman, John W ^b   Kim, In Hae ^b   Watanabe, Takaho ^b   Hammock, Bruce D ^b   Stewart, Janet ^a   Pollock, Jennifer S ^a   Pollock, David M ^a   Imig, John D ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOHEXYL 3 DODECYLUREA; EPOXIDE HYDROLASE; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME INHIBITION; GLOMERULUS; HYPERTENSION; KIDNEY FUNCTION; KIDNEY INJURY; MALE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 11144356945     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Zeldin DC: Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 276: 36059-36062, 2001
2. Campbell WB: New role for epoxyeicosatrienoic acids as antiinflammatory mediators. TiPS 21: 125-127, 2000
3. Imig JD: Eicosanoid regulation of the renal vasculature. Am J Physiol Renal Physiol 279: F965-F981, 2000
4. Roman RJ: P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev 82: 131-185, 2002
5. Capdevila JH, Falck JR: The CYP P450 arachidonic acid monooxygenases: From cell signaling to blood pressure regulation. Biochem Biophys Res Commun 285: 571-576, 2001
6. Imig JD, Falck JR, Wei S, Capdevila JH: Epoxygenase metabolites contribute to the nitric oxide-independent afferent arteriolar vasodilation to bradykinin. J Vasc Res 38: 247-255, 2001
7. Campbell WB, Gebremedhin D, Pratt PF, Harder DR: Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78: 415-423, 1996
8. Fissthaler B, Hinsch N, Chataigneau T, Popp R, Kiss L, Busse R, Fleming I: Nifedipine increases cytochrome P4502C expression and endothelium-derived hyperpolarizing factor-mediated responses in coronary arteries. Hypertension 36: 270-275, 2000.
9. s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem 276: 15983-15989, 2001
10. Node K, Huo Y, Ruan X, Yang B, Spieker M, Ley K, Zeldin DC, Liao JK: Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285: 1276-1279, 1999
11. Sun J, Sui XX, Bradbury A, Zeldin DC, Conte MS, Liao JK: Inhibition of vascular smooth muscle cell migration by cytochrome P450 epoxygenase-derived eicosanoids. Circ Res 90: 1020-1027, 2002
12. Zhao X, Pollock DM, Inscho EW, Zeldin DC, Imig JD: Decreased renal CYP2C enzymes and impaired vasodilation are associated with salt-sensitive hypertension. Hypertension 41: 709-714, 2003
13. Makita K, Takahashi K, Karara A, Jacobson HR, Falck JR, Capdevila JH: Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J Clin Invest 94: 2414-2420, 1994
14. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD: Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39: 690-694, 2002
15. Morisseau C, Goodrow MH, Dowdy D, Zheng J, Greene JF, Sanborn JR, Hammock BD: Potent urea and carbamate inhibitors of soluble epoxide hydrolases. PNAS USA 96: 8849-8854, 1999
16. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, Parker C, Graham L, Engler M, Hammock BD, Zeldin DC, Kroetz DL: Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87: 992-998, 2000
17. Davis BB, Thompson DA, Howard LL, Morisseau C, Hammock BD, Weiss RH: Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation. PNAS USA 99: 2222-2227, 2002
18. Sasser JM, Pollock JS, Pollock DM: Renal endothelin in chronic angiotensin II hypertension. Am J Physiol Regulatory Integrative Comp Physiol 283: R243-R248, 2002
19. Newman JW, Wantanabe T, Hammock BD: The simultaneous quantification of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J Lip Res 43: 1563-1578, 2002
20. Watanabe T, Morisseau C, Newman JW, Hammock BD: In vitro metabolism of the mammalian soluble epoxide hydrolase inhibitor, 1-cyclohexyl-3-dodecyl-urea. Drug Metab Dispos 31: 846-853, 2003
21. Zou LX, Imig JD, Von Thun AM, Hymel A, Ono H, Navar LG: Receptor-mediated intrarenal angiotensin II augmentation in angiotensin II-infused rats. Hypertension 28: 669-677, 1996
22. Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR: Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 7: 2364-2370, 1996
23. + channel activity. Am J Physiol Renal Physiol 270: F822-F832, 1996
24. Imig JD: Afferent arteriolar reactivity to angiotensin II is enhanced during the early phase of angiotensin II hypertension. Am J Hypertension 13: 810-818, 2000
25. Simon G, Abraham G: Angiotensin II administration as an experimental model of hypertension. In: Hypertension: Pathophysiology, Diagnosis, and Management, edited by Laragh JH, Brenner BM, New York, Raven Press, 1995, pp 1423-1435.
26. Stevenson KM, Edgley AJ, Bergstrom G, Worthy K, Kett MM, Anderson WP: Angiotensin II infused intrarenally causes preglomerular vascular changes and hypertension. Hypertension 36: 839-844, 2000
27. Chatziantoniou C, Daniels FH, Arendshorst WJ: Exaggerated renal vascular reactivity to angiotensin and thromboxane in young genetically hypertensive rats. Am J Physiol Renal Physiol 259: F372-F382, 1990
28. Ploth DW, Fitzgibbon W: Pathophysiology of altered renal function in renal vascular hypertension. Am J Kidney Dis 24: 652-659, 1994
29. Mulvany MJ: Structural changes in the resistance vessels in human hypertension. In: Hypertension: Pathophysiology, Diagnosis; and Management, edited by Laragh JH, Brenner BM, New York, Raven Press, 1995, pp 503-513.
30. Imig JD, Falck JR, Wei S, Capdevilla JH: Enhanced renal microvascular responsiveness to angiotensin II in hypertension is ameliorated by the sulfonimide analog 11, 12-epoxyeicosatrienoic acid. J Hypertens 19: 983-992, 2001.
31. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ: Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275: 40504-40510, 2000
32. Fornage M, Hinojos CA, Nurowska BW, Boerwinkle E, Hammock BD, Morisseau CHP, Doris PA: Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension 40: 485-490, 2002
33. Morrisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, Hammock BD: Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol 63: 1599-1608, 2002
34. Mitchell LA, Grant DF, Melchert RB, Petty NM, Kennedy RH: Linoleic acid metabolites act to increase contractility in isolated rat heart. Cardiovasc Toxicol 2: 219-230, 2002
35. Lombardi DM, Viswanathan M, Vio CP, Saavedra JM, Schwartz SM, Johnson RJ: Renal and vascular injury induced by exogenous angiotensin II is AT1 receptor-dependent. Nephron 87: 66-74, 2001
36. Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, Remuzzi A, Bertocchi F, Fagiani L, Remuzzi G, Ruggenenti P: Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 63: 1094-1103, 2003
37. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 33: 851-856, 1999
38. Matsuda H, Hayashi K, Arakawa K, Naitoh M, Kubota E, Honda M, Matsumoto A, Suzuki H, Yamamoto T, Kajiya F, Saruta T: Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: Role of intrarenal bradykinin. J Am Soc Nephrol 10: 2272-2282, 1999
39. Fenoy FJ, Scicli G, Carretero O, Roman RJ: Effect of angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captopril. Hypertension 17: 1038-1044, 1991
40. Goto K, Fujii K, Onaka U, Abe I, Fujishima M: Renin-angiotensin system blockade improves endothelial dysfunction in hypertension. Hypertension 36: 575-580, 2000
41. Kaergel E, Muller DN, Honeck H, Theuer J, Shagdarsuren E, Mullally A, Luft FC, Schunck WH: P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. Hypertension 40: 273-279, 2002
42. Kozak W, Klugar MJ, Kozak A, Wachulec M, Dokladny K: Role of cytochrome P-450 in endogenous antipyresis. Am J Physiol Regul Integr Comp Physiol 279: R455-R460, 2000
43. Nakashima T, Yoshida Y, Miyata S, Kiyohara T: Hypothalamic 11,12-epoxyeicosatrienoic acid attenuates fever induced by central inerleukin 1β in the rat. Neurosci Lett 310: 141-144, 2001.
44. Crook ED: The role of hypertension, obesity, and diabetes in causing renal vascular disease. Am J Med Sci 317: 183-188, 1999
45. Brenner BM: The epidemic of cardiovascular disease in end-stage renal disease. Curr Opin Nephrol Hypertens 8: 365-369, 1999